TRIP13 and head and neck cancer: Because it has been demonstrated that phosphorylation of TRIP13 at Y56 sensitizes head and neck cancer to the EGF receptor inhibitor cetuximab [23], we performed the clonogenic assay in all six cell lines, treated with or without cetuximab.